LONDON, STAINES, England and SAN FRANCISCO, March 30, 2011 (ots/PRNewswire) — Astellas Pharma Europe Ltd. and Medivation, Inc. today announced treatment of the first patient in the TERRAIN trial, a Phase 2 comparison of the investigational drug MDV3100, a triple-acting, oral androgen receptor antagonist, with bicalutamide, a commonly used non-steroidal anti-androgen, for the treatment of [...]
Tag Archive > Prostate Cancer Patients
Medivation and Astellas Complete Enrollment in Phase 3 AFFIRM trial of MDV3100 in Advanced Prostate Cancer
San Francisco and Tokyo, November 30 (ots/PRNewswire) – Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with [...]
Men, Partners and Patients in Europe United Against Prostate Cancer
Barcelona, Spain (ots/PRNewswire) – – New Survey Highlights Need for Education Resources, Critical Role of Physician in Patient Communication and Importance of Maintaining Normal Lifestyle During Treatment Findings from a survey of European prostate cancer patients, presented at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC) in Barcelona, Spain, highlight the need for further [...]
EANS-News: Epigenomics AG präsentiert Ergebnisse aus Prostatakrebs-Studie auf ASCO-Konferenz
Biomarker mPITX2 für die Prognoseeinschätzung bei Prostatakrebs erfolgreich validiert Erstes klinisches Labor in Deutschland wird mPTIX2-Test anbieten ——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Produkte/Forschung/Molekulardiagnostik Pressemitteilung, Berlin, und Seattle, USA, 29. Mai 2009 (euro adhoc) – Die Epigenomics AG (Frankfurt Prime Standard: ECX), ein Molekulardiagnostik- Unternehmen mit [...]
EANS-News: Epigenomics AG Presents Clinical Data from Prostate Cancer Prognosis Study at ASCO
Biomarker mPITX2 for prostate cancer prognostic application successfully validated First clinical laboratory in Germany to start offering mPITX2 testing service ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/research/Molecular diagnostics Press release, Berlin, Germany and Seattle, WA, USA, May 29, 2009 (euro adhoc) [...]
Committee for Medicinal Products for Human Use (CHMP) Recommends Granting Marketing Authorisation for FIRMAGON(R) (degarelix) for Treatment of Prostate Cancer
Saint Prex, Switzerland (ots/PRNewswire) – – New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) [...]
